Dr. William Wilcox
Medical Genetics (Clinical Genetics (M.D.) Physician)
At a glance
- Medical school
- University of California, Geffen School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
GA license 071200
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Galafold (migalastat hcl) | 60 |
| Palynziq (pegvaliase-pqpz) | 19 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Decatur, GA | 14 |
| Elfabrio (pegunigalsidase alfa-iwxj) | 14 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Decatur, GA | 13 |
| Elaprase (idursulfase) | 13 |
| Cerezyme (imiglucerase) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $4,106 in total to this clinician.
| BioMarin Pharmaceutical Inc. | $4,106 |
|---|
| Consulting Fee | $4,106 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 8 companies. The companies reported $745,279 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
BioMarin Pharmaceutical Inc. - Fabry Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00196742 - IRB00101017-18-PAGe Study
Amicus Therapeutics, Inc. - Gaucher disease outcome survey (gos) an observational, international, multicenter, long-term registry of patients with gaucher disease
Takeda Pharmaceuticals U.S.A., Inc. - An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
BioMarin Pharmaceutical Inc. - A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Sanofi US Services Inc. · Completed · NCT06019728 - A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
Genzyme Corporation · Active, not recruiting · NCT05206773 - A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Amgen Inc. - An Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia
Alexion Pharmaceuticals, Inc. - Pompe Disease Registry Protocol
Sanofi US Services Inc. · Recruiting · NCT00231400
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.